SHARDACROP Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,074 Cr
verified against source
Revenue YoY
9%
reported change
EBITDA
₹178 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Sharda Cropchem delivered Q1 FY27 revenue of Rs 1,074 crore (up 9% YoY) driven by favorable FX impact (+12.7%) offsetting volume decline (-1.6%). EBITDA grew robustly at 25% to Rs 178 crore with margin expansion of 220bps to 16.6%, supported by improved product mix and strong performance in NAFTA/LATAM. Europe, the largest market, saw temporary revenue softness due to heatwave-affected distributor destocking, though margins improved to 44.2%. PAT came in at Rs 88 crore including Rs 7.5 crore forex gain versus Rs 73.1 crore in Q1 FY26; on like-to-like basis PBT grew 16% YoY. Working capital improved by 10 days to 88 days. The company maintains FY27 guidance of 10-15% revenue growth with EBITDA margin of 18-20% and gross margin around 35%. Key risks include forex volatility due to EUR/USD sensitivity, unpredictable weather patterns affecting European destocking cycles, and LATAM margin pressure (declined to 16.9% from 28% YoY). Registration pipeline additions have slowed versus historical pace, raising questions on long-term growth visibility.
Colored figures show movement against the previous available record.
Guidance to track
- Management maintained full-year guidance targeting 10-15% revenue growth, supported by expected volume recovery in Europe and continued momentum in NAFTA/LATAM markets.
- On volume front, management expects 5-10% volume growth for the year, implying the remainder of FY27 should see better volume recovery after Q1 weakness.
- Company targets EBITDA margin in the 18-20% range for FY27, consistent with recent performance trajectory despite Q1 being at 16.6% due to unfavorable product mix.
- Management guides gross margin around 35% for the year, noting that Q1's 36.7% may moderate as Europe recovers and product mix normalizes.
Risks flagged
- EUR/USD movement created significant P&L volatility with forex gain dropping to Rs 7.5 crore from Rs 73.1 crore YoY, causing reported PAT to understate underlying operating performance. Analysts raised concerns about reporting transparency.
- LATAM gross margins declined sharply to 16.9% from 28% YoY despite strong revenue growth. Management attributed this to mix and competitive dynamics, not fully explaining the pressure.
- Analyst raised concerns that registrations added in past 3 years (less than 100) are significantly lower than the ~300 added in FY21-23, potentially impacting future growth pipeline. Management cited regulatory uncertainties as explanation.
- Depreciation and amortization run-rate is trending toward Rs 370-375 crore for FY27 versus Rs 325 crore last year due to intangible capex (registration costs) amortization, which could pressure future earnings.
Key quotes
- We don't manufacture anything anywhere in the world including India. We get everything manufactured as per requirement from the manufacturers mainly from China. So 100% is contract manufacturing.
- The process of registration is full of uncertainties. Nobody can say when will he receive the registration and at what cost.
- Last year quarter 1 June 25 had 73.1 crores of gain which is basically an unrealized gain on account of a sharp favorable movement of almost 10% in Euro USD whereas in the current quarter there is only 1% movement in the forex mainly euro so that has resulted in the higher exchange gain accounted in the last quarter versus current quarter.
Research modules